Vericel Corporation VCEL
- Market cap
- $2.0B
- P/E
- 82.6×
Follow VCEL
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.76 | 2.25 | 5.33 | 13.40 | 6.78 | 30.03 | 17.30 | 23.39 | 32.31 | 29.24 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 6.69 | 6.30 | 18.87 | 21.01 | 32.00 | 68.94 | 43.97 | 39.90 | 61.49 | 63.00 |
High Price
|
|||
| 202 | 205 | 216 | 241 | 273 | 281 | 305 | 314 | 357 | 398 |
Employees
|
|||
| 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
Revenue/Emp
|
|||
| 54 | 64 | 91 | 118 | 124 | 156 | 164 | 198 | 237 | 276 |
Revenue
|
|||
| 47.95% | 52.52% | 64.60% | 68.12% | 67.83% | 67.88% | 66.80% | 68.64% | 72.55% | 74.42% |
Gross Margin
|
|||
| (20) | (17) | (8) | (10) | 3 | (8) | (16) | (2) | 11 | 17 |
EBT
|
|||
| (35.98%) | (27.04%) | (8.96%) | (8.20%) | 2.45% | (4.85%) | (9.73%) | (1.20%) | 4.43% | 6.29% |
EBT Margin
|
|||
| (20) | (17) | (8) | (10) | 3 | (7) | (17) | (3) | 10 | 17 |
Net Income
|
|||
| 5 | 2 | 1 | 1 | 3 | 4 | 4 | 4 | 5 | 12 |
Depreciation
|
|||
| 2.36 | 1.92 | 2.26 | 2.67 | 2.75 | 3.36 | 3.49 | 4.15 | 4.86 | 5.49 |
Revenue/Sh
|
|||
| (0.85) | (0.52) | (0.20) | (0.22) | 0.06 | (0.16) | (0.35) | (0.07) | 0.21 | 0.33 |
Earnings/Sh
|
|||
| (0.86) | (0.40) | (0.01) | (0.16) | 0.39 | 0.62 | 0.38 | 0.74 | 1.19 | 1.03 |
Cash Flow/Sh
|
|||
| (0.06) | (0.05) | (0.07) | (0.06) | (0.06) | (0.17) | (0.16) | (0.58) | (1.31) | (0.54) |
Capex/Sh
|
|||
| (0.92) | (0.44) | (0.08) | (0.22) | 0.33 | 0.45 | 0.21 | 0.16 | (0.12) | 0.49 |
Free CF/Sh
|
|||
| 1.07 | 0.68 | 2.54 | 2.51 | 2.97 | 3.67 | 4.08 | 4.75 | 5.98 | 7.04 |
Book Value/Sh
|
|||
| 23 | 33 | 40 | 44 | 45 | 46 | 47 | 48 | 49 | 50 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 441.14 | 0.00 | 0.00 | 0.00 | 274.55 | 112.53 |
PE Ratio
|
|||
| 1.23 | 3.08 | 7.71 | 6.52 | 11.25 | 11.69 | 7.21 | 8.40 | 11.31 | 6.56 |
PS Ratio
|
|||
| 0.00 | 8.73 | 6.85 | 6.92 | 10.40 | 10.71 | 6.16 | 7.35 | 9.19 | 5.11 |
PB Ratio
|
|||
| 0.99 | 2.93 | 6.98 | 6.17 | 11.06 | 11.35 | 6.77 | 8.19 | 11.13 | 6.37 |
EV/Sales
|
|||
| (2.54) | (12.74) | (205.36) | (74.18) | 91.93 | 83.94 | 110.24 | 207.45 | (454.41) | 71.13 |
EV/FCF
|
|||
| (20) | (13) | 0 | (7) | 18 | 29 | 18 | 35 | 58 | 52 |
Op' Cash Flow
|
|||
| (1) | (2) | (3) | (3) | (3) | (8) | (8) | (28) | (64) | (27) |
Capex
|
|||
| (21) | (15) | (3) | (10) | 15 | 21 | 10 | 8 | (6) | 25 |
FCF
|
|||
| 32 | 37 | 98 | 92 | 101 | 132 | 149 | 160 | 162 | 198 |
Working Cap'
|
|||
| 10 | 17 | — | 28 | 53 | 50 | 48 | — | — | — |
Total Debt
|
|||
| (13) | (10) | (83) | (42) | (23) | (53) | (72) | (127) | (127) | (137) |
Net Debt
|
|||
| 25 | 23 | 102 | 111 | 134 | 170 | 192 | 226 | 292 | 355 |
Sh' Equity
|
|||
| (47.20%) | (33.51%) | (9.39%) | (7.11%) | 1.60% | (3.33%) | (6.47%) | (1.02%) | 2.64% | 3.59% |
ROA
|
|||
| (101.70%) | (72.51%) | (12.65%) | (10.16%) | 1.33% | (4.19%) | (8.86%) | (4.10%) | 1.71% | 3.18% |
ROIC
|
|||
| 118.26% | (390.25%) | (13.04%) | (9.06%) | 2.33% | (4.90%) | (9.21%) | (1.52%) | 4.00% | 5.11% |
ROE
|
|||
Vericel Corporation peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| NUVB Nuvation Bio Inc. | $2.0B | 0.0× | Compare |
| URGN Urogen Pharma | $2.0B | 0.0× | Compare |
| MESO Mesoblast Limited | $2.0B | 0.0× | Compare |
| AGIO Agios Pharmaceuticals, Inc. | $2.0B | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BHVN Biohaven Ltd. | $2.0B | 0.0× | Compare |
| LKFT Lakefront Biotherapeutics - Sponsored ADR | $2.0B | 0.0× | Compare |
| MRVI Maravai LifeSciences Holdings, Inc. | $2.0B | 0.0× | Compare |
| KOD Kodiak Sciences Inc. | $2.1B | 0.0× | Compare |
Vericel Corporation (VCEL) key facts
- Vericel Corporation (VCEL) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Net income was $16.5 million, or $0.33 per share (basic), a net margin of 5.98%.
- As of September 25, 2026, VCEL traded at $39.71, a market capitalization of $2.0 billion.
- At that price the stock trades at 82.6× trailing-twelve-month earnings and 6.6× sales.
- Return on equity was 5.11% and debt-to-equity 0.00.
Vericel Corporation (VCEL) Latest News
30 Jul
Vericel reports second quarter 2026 financial results, raises full-year guidance, and launches a share repurchase program. Raised full-year guidance combined with a share repurchase program signals stronger financial outlook and direct capital return to shareholders.
Vericel Q2 earnings call highlighted revenue growth, operational metrics, product pipeline updates and forward guidance for the company. Q2 earnings updates supply financial metrics and outlook that influence near-term investor sentiment and valuation.
30 May
Vericel Corporation revenue rose 20%. A biotech investor disclosed adding $63 million to the position. 20% revenue growth plus $63 million investor addition signals strong momentum likely to lift valuation and sentiment.
9 May
Vericel Corporation's Q1 earnings call highlights key financial results, revenue growth, product performance, and forward guidance for the year. Q1 earnings highlights cover financial performance, operational updates, and guidance that significantly shape investor sentiment and stock trajectory.
Analysts issued financial statements on Vericel Corporation's (NASDAQ:VCEL) first-quarter report. Analyst reactions to Q1 earnings report moderately influence financial performance perceptions and investor sentiment.
8 May
Vericel Corporation (VCEL) released the transcript of its Q1 2026 earnings call. Q1 2026 earnings transcript covers financial results, guidance, and strategic updates with potential to significantly influence VCEL's stock performance and trajectory.
Vericel Corporation held its Q1 2026 earnings call, covering financial results, operational updates, and forward-looking guidance for the company's cell therapy products. Quarterly earnings calls provide financial metrics and outlook that moderately influence near-term stock movement and sentiment without altering long-term strategy.
7 May
Vericel Corporation reported strong first quarter 2026 financial results, including revenue growth and profitability improvements, and raised full-year 2026 financial guidance for revenue and adjusted EBITDA. Raising full-year guidance after strong Q1 results signals robust growth and enhances investor confidence in future performance.
Vericel Corporation (VCEL) reported a first-quarter net loss but beat revenue estimates. Beating revenue estimates despite Q1 loss signals operational strength, moderately affecting financial performance and investor sentiment.
4 May
Wall Street analysts predict Vericel (VCEL) stock could surge 53.42%, urging investors to review details before betting. Analyst price targets indicate 53.42% upside for VCEL, signaling significant potential boost to investor sentiment and stock trajectory.
2 Apr
Vericel Corporation announces BARDA award valued at up to $197 million for procurement and advanced development of NexoBrid. BARDA award up to $197 million funds NexoBrid procurement and development, providing transformative revenue and validation for Vericel.
MediWound reports BARDA awarded Vericel a contract for NexoBrid valued at up to $197 million. BARDA contract up to $197 million delivers major funding and revenue potential for Vericel's NexoBrid product.
13 Mar
Vericel Corporation (VCEL) emerges as a prime investment opportunity driven by robust revenue growth in MACI and Epicel, expanding markets in orthopedics and burns, innovative pipeline including MACI 2.0, strong financials with profitability ahead, and undervalued stock relative to peers. Highlighting growth in core products and pipeline fosters moderate investor sentiment and potential financial uplift.
10 Mar
FDA approval for Vericel Corporation's (VCEL) Burlington MACI manufacturing facility could reshape its long-term growth narrative by improving production capacity and supply reliability. FDA approval enables Vericel's shift to a new MACI manufacturing site, significantly enhancing scalability and supporting accelerated revenue growth.
FDA MACI approval challenges Vericel Corporation's manufacturing capacity expansion and tests its long-term growth narrative. FDA approval expands MACI's market potential but strains Vericel's production scaling, significantly impacting revenue growth and stock performance.
9 Mar
Vericel Corporation (VCEL) secures FDA approval for commercial manufacturing of MACI. FDA approval for MACI commercial manufacturing boosts Vericel's production scale, revenue potential, and competitive position.
4 Mar
Vericel Corporation announces FDA approval of its new state-of-the-art advanced therapy manufacturing facility. FDA approval of a state-of-the-art manufacturing facility boosts Vericel's production capacity, scalability, and competitive edge in advanced therapies.
28 Feb
MediWound highlighted robust NexoBrid growth, accelerated EscharEx Phase III trial timeline to start mid-2025, and ongoing BARDA discussions for stockpiling at Oppenheimer Conference. NexoBrid growth updates boost Vericel's North American commercialization revenues, while EscharEx and BARDA progress enhance pipeline value.
Vericel Corporation (VCEL) posted record 2025 results and issued upbeat growth guidance for 2026, prompting analysis of its current valuation amid strong performance outlook. Record 2025 results and upbeat 2026 guidance highlight major financial strength and growth potential, significantly boosting VCEL's trajectory and investor sentiment.
27 Feb
Vericel Corporation released Q4 earnings call highlights detailing financial performance, revenue growth, product updates, and 2024 guidance. Q4 earnings highlights reveal key financial results and forward guidance significantly influencing stock trajectory and investor sentiment.
26 Feb
Vericel Corporation (VCEL) released Q4 2025 earnings call summary detailing financial results, revenue growth, and strategic outlook. Q4 earnings summaries highlight key financial metrics and guidance that significantly influence stock trajectory and investor sentiment.
Vericel Corporation (VCEL) reported record revenue and strategic growth in its Q4 2025 earnings call highlights. Record revenue and strategic growth signal significant positive shifts in financial performance and market trajectory for VCEL.
Vericel (VCEL) Q4 2025 earnings call transcript details financial results, operational updates, and forward guidance. Q4 earnings call transcript discloses quarterly financials, revenue growth, and strategic outlook significantly influencing investor sentiment and stock trajectory.
Vericel Corporation reported fourth quarter and full-year 2025 financial results. Quarterly and annual earnings reports significantly shape investor expectations, stock price movements, and future market performance.
10 Feb
Vericel Corporation is highlighted in the context of the tissue and regenerative engineering market, which is experiencing increased funding from both company initiatives and government sectors. This surge in financial support is expected to drive innovation and growth within the industry, potentially benefiting companies like Vericel that are involved in regenerative medicine and tissue engineering. Increased funding in the regenerative engineering market may moderately influence Vericel's financial performance and competitive positioning.
16 Jan
Vericel Corporation (VCEL) is highlighted among high-growth tech stocks in the US as of January 2026, showcasing its innovative approaches and potential for significant market impact. The company is positioned to leverage advancements in biotechnology, particularly in regenerative medicine, which could enhance its competitive edge and financial performance. Investors are encouraged to consider VCEL's growth trajectory amidst evolving market dynamics. Vericel's advancements in biotechnology and regenerative medicine are likely to significantly impact its market performance and investor sentiment.
13 Jan
Vericel Corporation announced its preliminary financial results for 2025, highlighting a projected revenue increase driven by strong demand for its products. The company also provided updates on ongoing clinical trials and strategic initiatives aimed at expanding its market presence. Management expressed optimism about future growth prospects and reaffirmed its commitment to innovation in regenerative medicine. The projected revenue increase and strategic initiatives indicate significant potential for future growth and market performance.
6 Jan
Vericel Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. This event is a significant opportunity for the company to showcase its innovations and engage with investors and industry leaders. Participation in a major healthcare conference can enhance visibility and investor interest, potentially impacting market sentiment.
18 Dec
Vericel Corporation (VCEL) is highlighted among high-growth tech stocks to watch in December 2025, indicating strong market interest and potential for significant advancements in its product offerings and financial performance. The company is positioned to capitalize on emerging trends in the biotech sector, which may enhance its competitive edge and investor appeal. Vericel's inclusion as a high-growth stock suggests significant strategic moves and potential product innovations that could impact its market trajectory.
16 Dec
Vericel Corporation is gaining attention due to its recent advancements in regenerative medicine, particularly with its innovative therapies for treating severe skin wounds and cartilage damage. The company has shown promising growth in its product sales and is expanding its market presence. Investors are encouraged to consider the potential of Vericel's unique offerings and their impact on the healthcare sector, especially as the demand for effective regenerative treatments continues to rise. Vericel's advancements in regenerative medicine and expanding market presence are likely to significantly impact its future performance and investor sentiment.